Latest Conference Coverage

Changing the Treatment of Diabetic and Inflammatory Neuropathies: Brian Callaghan, MD, MS

The associate professor at the University of Michigan provided insight on new guidelines to treat painful diabetic neuropathy. [WATCH TIME: 2 minutes]

Givosiran Shows Long-Term Clinical Benefit in Acute Hepatic Porphyria, Open-Label Findings Suggest

Potential Temporal Association Found Between Guillain-Barré Syndrome and COVID-19 Vaccination in Pediatrics

From the pre-COVID period to 6 weeks after vaccination, the reporting rate of GBS was significantly different, regardless of whether Brighton criteria was applied to the analysis. The authors noted that passive surveillance limitations warrant further analysis.

CNM-Au8 Displays Evidence of Survival Benefit in Amyotrophic Lateral Sclerosis

Results from phase 2 RESCUE-ALS trial show that treatment with CNM-Au8 in ALS demonstrated improvement in survival compared to the estimated median survival rate.

Design of Phase 3 URSA Study of Tolebrutinib in Myasthenia Gravis Detailed

The phase 3 study, paused at US sites by the FDA, seeks to enroll 154 individuals with generalized myasthenia gravis, both seropositive and seronegative.

High Proportion of Zilucoplan Responders Identified in Secondary Analysis of RAISE Trial

After 12 weeks of treatment with zilucoplan 0.3 mg/kg, almost three-fourths of patients demonstrated at least a 3-point reduction in Myasthenia Gravis Activities of Daily Living scores.

Cipaglucosidase Alfa/Miglustat Shows Beneficial Treatment Effects for Patients With Late-onset Pompe Disease

Most ambulatory patients had improved pulmonary functions and biomarker outcomes with cipaglucosidase alfa/miglustat that were sustained through a less than 36-month follow-up period.

Endovascular Therapy Shows Better Functional Outcomes for Acute Stroke

Migraine Linked to Increased Risk of Parkinson Disease in the Middle-aged and Older Population

A study presented at the MDS Congress 2022 found an association between migraine and the incidence of Parkinson disease in the middle-aged and older population.

IncobotulinumtoxinA Supported for the Treatment of Neurological Disorders in Adults

Results from a pooled analysis extend and support the safety and the tolerability of the use of incobotulinumtoxinA for the treatment of adults with neurological disorders.

Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease

One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.

Selective Adenosine A2A Antagonist KW-6356 Demonstrates Efficacy, Safety as Adjunct to Levodopa in Parkinson Disease

The Parkinson disease agent showed a safe and tolerable profile, with significantly greater improvements in MDS-UPDRS-III scores and OFF time per day.

NeurologyLive® Brain Games: September 18, 2022

Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder

Danielle Kipnis, MA, of Columbia University, discussed key components of a yoga program for individuals with functional neurological disorder and from the evaluation, found it feasibility as an intervention.

Multiple-Source Constant-Current DBS Improves Quality of Life in Parkinson Disease, Real-World Analysis Suggests

Over a 2-year period, patients demonstrated improvements in Parkinson’s Disease Questionnaire scores, along with a 35% improvement in MDS-UPDRS-III scores.

NeuroVoices: Lynn Bekris, PhD, on Future Research for sTREM2, GFAP, and Immunotherapies in Alzheimer Disease

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.

NeurologyLive® Brain Games: September 11, 2022

NeuroVoices: Lynn Bekris, PhD, on sTREM2 and GFAP to Differentiate Cognitive Status, Trajectory

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.

NeurologyLive® Brain Games: September 4, 2022

Role of the Cognitive Stress Test in Improving Future Alzheimer Clinical Trials: Rosie Curiel, PsyD

Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD

Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]

NeurologyLive® Brain Games: August 28, 2022

Expanding on the Cognitive Stress Test and Answering Cognitive Deficit Questions: Rosie Curiel, PsyD

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]

The Realities of Gender-Targeted Therapeutics for Alzheimer Disease: Jessica Caldwell, PhD

The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]

NeurologyLive® Brain Games: August 21, 2022

Lessons About Alzheimer Disease and Related Dementias From GFAP, sTREM2 Astrocytes: Lynn Bekris, PhD

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]

NeuroVoices: Jessica Caldwell, PhD, on Evaluating Brain Regions and Functional Connectivity to Understand Sex Differences in Cognitive Decline

The director of the Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed new research which looked at the differences in functional connectivity for men and women of older age.

Changes in Vocation as Early Signs for Alzheimer Disease, Cognitive Issues: Alvaro Pascual-Leone, MD, PhD

The chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]

NeurologyLive® Brain Games: August 14, 2022

Raising the Awareness of Severe Preeclampsia and Recognizing Potential Long-Term Impacts

Vesna Garovic, MD, PhD, chair of the nephrology division at Mayo Clinic, discussed the appropriate reaction to data suggesting late-life elevated inflammation and neurovascular damage from severe preeclampsia.